Nitrosamine risk management.

Nitrosamine control is a portfolio-scale knowledge and evidence problem. Risk can originate in API synthesis, recovered solvents, reagents, excipients, water, cross-contamination, packaging, storage or the API’s own amine structure.¹ Acceptable intakes and technical expectations evolve, and one supplier or formulation change can alter conclusions across many products and markets.

The decisions cross chemistry, toxicology, suppliers, analytical laboratories, manufacturing, stability, quality and regulatory. Each function can hold its own evidence well and still lose the dependency between them. Seal keeps the relationship from each scientific assumption to the product decisions it supports, so a revised limit or newly understood pathway is traced forward rather than rediscovered product by product.

1Define the portfolio and the compounds it can form.

The assessment universe is the portfolio: API and salt, dosage form, strength, maximum daily dose, treatment duration, formulation, manufacturing and packaging sites, material sources, process versions and markets. Each product carries a status that distinguishes screened, potentially at risk, confirmatory testing required, mitigated, controlled, temporarily accepted and under reassessment.

Compound records keep small-molecule nitrosamines and nitrosamine drug substance-related impurities (NDSRIs) distinct, with structure, identifiers, precursor relationship, predicted potency category, analytical standards and the acceptable intake with its source. One compound can reach different conclusions by route, duration, product or jurisdiction, and those conclusions stay versioned.²

1.1Why teams choose Seal for nitrosamine risk

When an acceptable intake is revised, every product assessment that used it has to be found and reopened, and with per-product documents, limits calculated in spreadsheets and supplier data held in email, that is done by hand. The pathway, material knowledge, acceptable intake, product limit, test results and market actions are connected, and each limit is calculated from versioned inputs. A new limit or supplier disclosure identifies the dependent products, results, batches and filings for reassessment.

2Model the formation pathway, not a summary of it.

A pathway needs a vulnerable amine or susceptible structure, a nitrosating source such as nitrite and conditions that allow the reaction: pH, solvent, temperature, water activity, time, sequence, quench, recycle, packaging and storage. Each pathway in Seal records the evidence for presence, absence, prevention, purge or remaining uncertainty, and the process stages and products it can affect.

Materials carry their trace contributions. Starting materials, reagents, recovered solvents, water, excipients, packaging materials and shared equipment keep their amine and nitrite knowledge, test results, variability and supplier change obligations. A compendial excipient grade does not, by itself, establish a suitably low nitrite contribution for every formulation.

3Assess each product against its own process.

The risk conclusion follows from pathway plausibility, precursor levels, process conditions, purge, equipment and campaign history, formulation, package, dose, duration, analytical capability and prior results. Seal keeps the cited evidence and calculations with the conclusion rather than reducing the assessment to a questionnaire answer, so a reviewer can see why a product was screened out as well as why another needs testing.

4Hold acceptable intakes as versioned decisions.

An acceptable intake has an authority source, publication date, structural basis, interim or final status, numerical limit, rationale, reviewer and effective date.¹ When it is revised, Seal identifies the dependent specifications, methods, results, products, markets, filings, inventory and prior decisions for reassessment.

Product limits are calculated from the acceptable intake, maximum daily dose, dosage units, strength and reporting basis, including how multiple nitrosamines are combined and how values are rounded. Every product-limit version keeps its inputs and the inventory population it applies to, so the calculation can be reproduced for any batch.

Swipe to see the full diagram →

5Test to answer the risk question.

The analytical strategy follows the question being asked: screening, targeted confirmatory testing, NDSRI-specific methods, formation studies, raw-material testing or stability monitoring. Method capability is judged against the product-specific limit, not a generic reporting threshold. Reference standards, calibration, chromatograms, integration, blanks and system suitability stay attributable, and Seal connects the source data to each result while retaining every reintegration, exclusion and repeat.

Confirmatory testing needs a representative population across strengths, sites, suppliers, process versions, packaging and storage ages, with the selection rationale visible. One conveniently available batch cannot stand for a diverse global portfolio without justification. Results translate into patient exposure and margin against the current acceptable intake, and below-quantitation, estimated, confirmed, invalid and not-tested states remain distinct.

Stability data separates an impurity introduced during manufacture from one that forms on the shelf. Long-term, accelerated and stress results, package and headspace conditions, and any antioxidant or inhibitor stay linked to the shelf-life model, so a late increasing trend cannot be hidden by an early clean result.

6Mitigate the pathway and act on batches and markets.

Each mitigation connects to the pathway it interrupts: a supplier control, a tighter nitrite limit, a process sequence or pH change, a quench or purge step, a formulation change with an antioxidant, a package or a shorter shelf life. Development, validation, stability, bioequivalence, supply and filing dependencies stay in one plan.

Batch and inventory decisions resolve against the effective limit and control strategy: release, hold, retest, rejection or recall assessment for specific API lots and drug-product batches, with distributed quantity and shortage considerations visible. A market action can be scoped without changing the scientific record for unaffected products. Regulatory communication resolves by application and market, and Seal distinguishes guidance recommendations, approved commitments and internal targets.

7Reassess when the science or the supply changes.

A new API route, recovered solvent, excipient source, nitrite level, package, method or quality-agreement change traverses every pathway and product that relied on the earlier knowledge. Changed evidence can narrow or widen the risk without recreating assessments by hand.

Periodic review watches for new compounds, acceptable-intake updates, analytical advances, internal results, stability trends and authority communications. The review records what changed, which assumptions still hold, the affected products and the actions, owners and completion evidence.

8Prove one difficult product family end to end.

Follow an API with secondary amine functionality through route and supplier assessment, excipient nitrite data, the NDSRI pathway, acceptable-intake rationale, product-limit calculation, method validation, representative testing, stability, mitigation, market filings, inventory controls and periodic reassessment.

Include an updated acceptable intake, an unknown supplier nitrite range, a below-LOQ result, a confirmed late-shelf-life finding, a reformulation, one market using an interim limit and a batch already distributed. The system must recompute every affected decision without losing the historical basis.